In the complex landscape of sleep medicine, chronic insomnia remains one of the most pervasive and challenging conditions to treat. Affecting millions globally, the disorder often leads to a cycle of pharmaceutical reliance, daytime fatigue, and long-term health complications. However, a new clinical development from Vivos Therapeutics Inc. is shifting the conversation toward non-pharmacological, mechanical interventions.
According to recently released, albeit unpublished, clinical data, the company’s "Vida" oral appliance has demonstrated remarkable efficacy in treating patients with moderate to severe insomnia. In a single-site study, 100% of participants reported symptomatic improvement, with an average reduction of 65% in Insomnia Severity Index (ISI) scores. These findings offer a potential paradigm shift in how clinicians approach the management of sleep-disturbed patients.
The Core Data: Quantifying Sleep Recovery
The study, conducted between 2022 and 2025, focused on a cohort of 37 adult patients ranging in age from 28 to 77. The group, consisting of 30 women and 7 men, all presented with long-standing, clinically documented cases of moderate to severe insomnia.
The methodology was straightforward: participants utilized the Vida oral appliance nightly for an average duration of 3.7 months. Researchers tracked progress using the Insomnia Severity Index (ISI), a validated tool used by medical professionals to quantify the severity of both nighttime and daytime components of insomnia.
The results were statistically significant. By the conclusion of the observation period, the average ISI score across the group dropped by approximately 65%. Most importantly, the clinical response was universal: every single participant improved by at least one full ISI classification level. By the end of the study, the entire cohort had moved out of the moderate-to-severe range, with all subjects classified as having either "no clinically significant insomnia" or "subthreshold insomnia."
Chronology of the Vida Development
To understand the weight of these findings, one must look at the evolution of the technology. The Vida appliance is not an entirely new invention but rather an evolution of the "Pod" oral appliance, a device originally developed by Advanced Facialdontics. Vivos Therapeutics acquired the technology in early 2023, seeing its potential for broader applications in sleep-disordered breathing.
The device relies on proprietary "Unilateral BiteBlock Technology," invented by Dr. Scott Simonetti. Historically, the device was cleared by the U.S. Food and Drug Administration (FDA) as a Class II medical device specifically for the management of bruxing (teeth grinding) and clenching associated with Temporomandibular Disorder (TMD).
The shift toward using the device for insomnia began as clinicians noted the secondary benefits of the appliance on sleep quality. Between 2022 and 2025, Dr. Simonetti oversaw the clinical study that would eventually serve as the basis for Vivos’s current announcement. While the FDA has not yet reviewed or cleared the device specifically for the treatment of insomnia, Vivos has stated that they have received counsel indicating the current data set is sufficient to proceed with clinical integration without additional regulatory hurdles for this specific application.
The Science of Autonomic Balance
The mechanism behind the Vida appliance’s success in treating insomnia is rooted in the interplay between the oral cavity and the autonomic nervous system.
"I believe the Vida helps modulate autonomic nervous system balance during sleep," explains Dr. Scott Simonetti. "The consistency of improvement across all 37 patients in the study suggests real potential for broader clinical adoption as awareness and supporting data continue to emerge."
Many patients suffering from chronic insomnia exist in a state of hyperarousal, where the sympathetic nervous system remains overactive even during the hours intended for rest. By stabilizing the jaw and oral posture, the Vida appliance may mitigate the physical stressors that trigger this nervous system imbalance, allowing the body to transition more effectively into the restorative stages of sleep.
Addressing COMISA: The OSA-Insomnia Connection
A critical context for this study is the high prevalence of Comorbid Insomnia and Obstructive Sleep Apnea (COMISA). Medical literature suggests that up to 60% of patients diagnosed with moderate to severe obstructive sleep apnea also suffer from chronic insomnia.
The dual diagnosis is notoriously difficult to treat; traditional CPAP therapy often fails to address the psychological or autonomic components of the patient’s insomnia, while sedatives can sometimes worsen apnea symptoms. Vivos Therapeutics aims to position the Vida appliance as a bridge—a non-pharmacological, comfortable, and mechanical solution that addresses the physical manifestations of sleep disturbance without the side effects often associated with prescription sleep aids.
Official Perspectives and Executive Strategy
R. Kirk Huntsman, Chairman and CEO of Vivos Therapeutics, views the study as a validation of the company’s long-term strategy to address sleep disorders holistically.
"The results of this clinical study are consistent with what we’ve seen with thousands of COMISA patients," Huntsman stated in a press release. "Symptomatic relief comes fast, with no material safety issues, and appears to have lasting effects—all at a reasonable cost."
From a business perspective, the implications are significant. Vivos estimates that it may generate approximately $2,000 per patient through a combination of diagnostic testing and the provision of the appliance. While the company acknowledges that the appliance itself is not typically covered by standard insurance—meaning patients will likely pay out-of-pocket—the demand for non-pharmacological, effective sleep interventions remains high. Home EEG testing, which often accompanies the diagnosis, may still be eligible for insurance reimbursement, providing a pathway for integration into existing clinical workflows.
Implications for Future Clinical Practice
The implications of this study are twofold: they offer a potential new revenue stream for sleep-focused dental and medical practices, and they offer a new clinical pathway for patients who have exhausted traditional options.
1. Shift Toward Non-Pharmacological Treatment
For years, the gold standard for insomnia treatment has been Cognitive Behavioral Therapy for Insomnia (CBT-I) and sleep hygiene, followed by pharmaceutical intervention. However, access to CBT-I specialists is limited, and many patients are wary of the side effects of sleep medication. The Vida appliance represents a "low-barrier" intervention that can be administered in a dental or sleep clinic setting.
2. The Role of the Dentist in Sleep Medicine
This development reinforces the growing role of dentists in the sleep health ecosystem. Because the Vida appliance requires precise fitting and adjustment, the collaboration between sleep physicians and dentists becomes essential. As data continues to emerge, it is likely that oral appliance therapy will move further toward the center of sleep medicine, rather than remaining an alternative secondary to CPAP.
3. Regulatory and Market Considerations
While the data is promising, the path forward will require navigating the regulatory landscape. Although Vivos has received advice that the current data is sufficient to proceed, broader adoption will likely depend on peer-reviewed publication of these results in major medical journals. This would allow the medical community at large to scrutinize the findings and compare the Vida’s outcomes against existing therapies.
Conclusion: A New Chapter for Sleep Health
The study of 37 patients, while small in the context of global insomnia statistics, provides a compelling look at how mechanical, non-invasive technology might address one of the most stubborn health issues of the 21st century. By achieving a 65% reduction in insomnia severity, the Vida appliance has signaled that the answer to better sleep may not always lie in a bottle of pills, but in the structural alignment of the airway and the autonomic balance of the nervous system.
As Vivos Therapeutics prepares to expand its reach, the focus will now shift to scaling the treatment and gathering more longitudinal data. For the millions of patients currently struggling to find a sustainable way to sleep through the night, the Vida appliance represents more than just a piece of medical equipment; it represents a return to the restorative, essential act of rest. Whether this technology will eventually become a standard of care for chronic insomnia remains to be seen, but the initial evidence is, by all clinical accounts, a significant step forward.
